Patient information leaflet legal requirement

In the European Union (EU), these are called Package Leaflets (PLs). PILs have been a legal requirement in the UK since 1999 for all medications. The user testing of PILs has been implemented as evidence since 2005 so that people can rely on the information provided in the leaflet Among those he mentioned: A typical patient information leaflet has about 1600 words, but about 450 of those are specified by the template in the legislation It sets out the legal framework for patient information leaflets as described in national legislation and it describes best practice for information design to ensure that patients who rely on the..

Medicines must include a patient information leaflet (PIL) if the label does not contain all the necessary information. See best practice guidance on the labelling and packaging of medicines. You.. Legal framework All medicinal products placed on the Community market are required by Community law to be accompanied by labelling and package leaflet which provide a set of comprehensible information enabling the use of the medicinal product safely and appropriately written medication information for patients that the goals of the final rule would be met more effectively and with greater innovation without regulation (47 FR 39147, September 7, 1982)

medicine by both the patients and healthcare professionals. Thus, the approval of the label and package leaflet is an intrinsic part of the authorisation process for all medicinal products. The detailed requirements for the information to be included in labels and leaflets are specified in Articles 54-69 of Directive 2001/83/EC Manufacturers are reminded that the requirements for patient implant cards (Implant Cards) and patient information leaflets (Information Leaflets) are to be phased in from 1 December 2018. What.. The patient acknowledged that the monograph supplied when the medication was dispensed bore a summary of package insert information and a relevant patient medication guide mandated by the FDA. She also acknowledged that the monograph was written in nontechnical, lay language so patients and caregivers could understand the information A patient information leaflet is a technical document included in every medicine package to offer written information about the medication. Patient information leaflets (PILs) are provided by the manufacturer following a standard template consisting of the same types of information for every medication CFR - Code of Federal Regulations Title 21. The information on this page is current as of April 1 2020. For the most up-to-date version of CFR Title 21, go to the Electronic Code of Federal Regulations (eCFR). Sec. 310.501 Patient package inserts for oral contraceptives. (a) Requirement for a patient package insert

User Testing Policy on Patient Information Leaflets for Parallel Importers June 2019 1. BACKGROUND Patient Information Leaflets (PILs) have been a legal requirement in the UK since 1999 for all medicines. Survey findings tell us that patients want more information than they currently receiv Information to Patients - Legislative approach. Based on the analysis of current practices and of risks and benefits for patients, the Commission believes the time has come to improve the quality of information available to patients on medicinal products. The balance between the benefits and risks of providing information indicates the need for. The General Regulations made in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), require a Patient Informational Leaflet (PIL) to accompany each medicine (regulation 12). As such, the PI is required by the Authority to be included in the application for the registration of a medicine (regulation 16(3)(g)) Changes to the European legislation made in 2004 introduced a legal requirement to ensure that all patient information leaflets reflect the results of consultations with target patient groups. Consequently, consultations with target patient groups is required on the mock-up of the package leaflet, however, articles 59(3) and 61(1) of Directive.

patients. This leaflet introduces you to our practice. This is a mixed practice providing private care and NHS services. Cliff Wetton, the practice principal and owner, sees patients predominantly on a private basis. Ashee sees patients on a private basis on Saturdays. Details of the current private fees are available on our website Patient information Leaflets (PILs) are intended to supplement and not replace the advice given to patients by health professionals. BOC Healthcare has a PIL for each of its licensed medical gases, the content and layout of which has been approved by the MHRA • The patient must be competent (have capacity) *Every adult patient is presumed competent unless proven otherwise *An unwise or eccentric decision does not mean incompetence • The patient must have received sufficient information to make an informed decision *To include details on the risks, benefits and available alternative

Practice leaflet requirements. The clinical governance requirements for pharmacies, set out in paragraph 28(2)(a)(i) of Schedule 4, Part 4, of the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013, a requirement that the pharmacy contractor (P) produces in an approved manner, and makes available in an appropriate manner, a practice leaflet. 1.1 The role of the patient information leaflet in an information-rich society 8 1.2 Why patient information leaflets need improvement 9 1.3 Establishing a Working Group of the Committee on Safety of Medicines 10 1.4 Setting priorities 11 2 History of patient information in the United Kingdom and the legislative framework 1 Patient information leaflets - Consumer preferences. Rachel Croome Director, Business Improvement and Support Medical Devices Branch Patient information leaflets, 1 March 2018. Slide 1 - Patient information leaflets. Scope of requirement is the same for patient information leaflets as for patient implant cards On 7 March 2013, the European Commission adopted a black triangle as the symbol to be placed on the patient information leaflets and the Summary of Product Characteristics (SmPC) of medicinal products subject to additional monitoring in the European Union (EU). The history of the black triangle The requirement to include a. As the dust settles on Brexit, it is interesting to consider the impact on the user testing of Patient Information Leaflets (PILs), which was originally a requirement under European law, Article 59(3) of Directive 2001/83/EC as amended by Directive 2004/27/EC. PIL regulation is now governed by UK law, with guidance on the production of PILs [

Medication Guide to a patient may be all that a REMS requires, or it might be part of a REMS that also includes elements to assure safe use, such as certification requirements for healthcare providers and/or pharmacies. This discussion focuses on providing practical information for health- system pharmacists on Medicatio Introduction. Comprehensible leaflets are an effective teaching aid in patient counseling [1, 2].However, many leaflets are introduced without scrutinizing their suitability for the intended audience and thus, they are often not effectively used by patients [2- 5].Various requirements for high-quality leaflets have been published [4, 6- 8].However, a standardized and easy-to-apply guidance. PRIVACY POLICY. PATIENT INFORMATION LEAFLET. REPORT A SIDE EFFECT. Emla Cream. For topical anaesthesia of the skin. Always read the label. This website is intended for a UK audience only. UK Branch, Aspen Pharma Ireland Limited. Trademarks are owned by or licensed to the Aspen group of companies The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged

[Drug Information for Patients (Package Leaflets), and

Experts and patients examined patient information leaflets from 30 common medicines, following European Union Directive 92/27 EEC, which outlined the legal requirements for patient information leaflets. The scoring system allowed a direct comparison between the outcomes of expert and patient examinations Extract * Notwithstanding the growth of electronically-mediated information, for many people the primary or only source of information about their medicine still remains the patient information leaflet (PIL).1 The PIL became a legal requirement in 1992 when the European Commission issued Directive 92/27/EEC on the labeling of medicinal products for human use and on package leaflets.

Make it a legal requirement for health care providers to give individuals Patient information leaflets from the vaccine manufacturers prior to all vaccinations. More details All medications in the UK are required by law to include a patient information leaflet so that the individual can be fully informed prior to using the medication The European Commission (EC) has published a report recommending improvements in the summary of product characteristics (SmPC) and the Patient Information Leaflet (PIL) of medicinal products for human use. The report identifies shortcomings concerning the SmPC and the PIL, and provides recommendations on the way in which SmPC and PIL could be.

Usability as a legal requirement: leaflets for medicines

Limited literacy is associated with a nearly twofold increase in mortality in older patients. The aim was to assess the readability level of patient information leaflets in Ireland. The SMOG formula is a validated tool to assess readability of text, providing an estimate of the years of education needed to understand a piece of writing. We evaluated 45 common patient information leaflets for. Section 856 IAC 1-33-2 - Patient counseling requirements. Authority: IC 25-26-13-4. Affected: IC 25-26-13-16. Sec. 2. (a) Upon the receipt of a prescription or upon the subsequent refilling of a prescription, and following a review of the patient's prescription medication profile, the pharmacist shall be responsible for the initiation of an offer, as set forth in section 1.5(a) of this rule. The course will also provide practical advice on designing and writing Patient Information Leaflets and Package Inserts to meet regulatory requirements and satisfy readability and compliance needs. In the face of increasing regulatory and consumer demand, the need for accurate and complete product information has never been stronger Patient confidentiality is a legal requirement which is upheld by HomeLink Healthcare. When you agree to receive our services, we will require your consent to share any of your information. We ensure that your care is delivered in accordance with the regulatory guidelines regarding patient confidentiality and data protection

Best practice guidance on patient information leaflets

Patient Information Leaflet User Testing Sign-up Form In order to ensure that pharmaceutical companies are writing medical information that can be easily understood by patients, there is a legal requirement to test 'Patient Information Leaflets' Background: Patient information leaflet (PIL) which accompanies medicinal products and informs patients about dosage, side effects, etc., is known as a tool which empowers patients to be more involved in making decisions related to their medications and health. In recent years, policy makers have paid much attention to PIL and its lay-friendliness i.e. being clear,explicit, and easy to read. It is a legal requirement that data submitted for evaluation should substantiate all claims and should meet technical requirements of quality, safety and efficacy of the product for the purposes for which it is intended. The Guidelines are meant to guide the applicant in meeting the requirements of the Act. I Patient Information Leaflet PRACTICE INFORMATION. STRAND MEDICAL Page 2 Introduction advice and immunisation requirements, as available on the NHS. In line with NHS policy, we operate as a group practice, which means that patients are not registered with a specific Doctor

Historically, many leaflets were in general poorly laid out and too lengthy due to the complexity of the Summary of Product Characteristics (SmPC) and / or information being given in scientific language in order to fulfil regulatory requirements. Patients quickly lost interest in the document, failing to read or understand information crucial. Implant card and patient leaflet requirements are already implemented for new devices in Australia and non-exempted devices must be accompanied by both implant cards and patient leaflets. Existing devices (i.e. released prior to release of the ruling) are still under a grace period for implementation until 1st December 2021 1. Background1.1. The provision of medicine information leaflets. Medicine information leaflets are expected to increase consumers' knowledge of medicines, assist in distinguishing side effects and recognising interactions, and improve consumers' health management skills. 1 In New Zealand there are ethical requirements that patients are fully informed about their prescribed medicines.2, 3. 5.1 Principles for producing patient and carer information 8 5.2 Minimum requirements for patient and carer information 9 5.3 How information is provided to patients to support their decision making, including risks, benefits and alternatives 9 5.3.1 Assessment 9 5.3.2 How the discussion and provision of information to patients is recorded

the patient information leaflet followed by provision of leaflets to the patients. After allowing the patients to read the leaflet for a period of 20 min, patients have again been administered with a set of questions to assess their knowledge. The Flesch Reading Ease and Flesch-Kincaid Grade Level readability scores achieved fo 4.5.3 Support the Patient Information Librarian in offering advice and leaflet authors and UHL services. 4.5.4 Help to create and manage an archive of previous versions of patient information leaflets. 4.5.5 Prepare reports and compliance data for reporting to the Consent & Mental Capacity Act Committee and the Executive Quality Board The leaflets are usually printed on thin, recycled or recyclable paper, but there are a range of substrates available. The printing and folding format is often adapted to the volume of information and the production procedures to ensure ease of use on the packaging lines. All patient information leaflets must meet EU legislation and MHRA rules

Medicines: packaging, labelling and patient information

Guidance. 4.3.1 In exceptional circumstances, you may be justified in releasing confidential patient information without their consent if doing so is in the best interests of the public or the patient. This could happen if a patient puts their own safety or that of others at serious risk, or if information about a patient could be important in preventing or detecting a serious crime Health Canada has identified the need for patients to receive clear information about the safe use of opioids and the risks associated with their use. As such, requirements have been added, under the Food and Drug Regulations, for a warning sticker and patient information handout to be provided with all prescription opioids that appear in Part.

While the law requires a Patient Information Leaflet for every medicine, when and how these are given to patients varies. It seems that too often these are given to the patient after the treatment has been prescribed or administered rather than before. It has been brought to our attention that senior managers in some NHS Trusts are also instructing staff involved in the rollout of COVID-19. More specifically, we find that the new patient information leaflet template proposed here provides better information findability. Introduction Patient information leaflets (PILs) are an example of a text 'genre', i.e. a class of documents that displays a conventional structure Patient Information Leaflets. To comply with regulations, patients should be provided with a Patient Information Leaflet (PILs) for their prescribed medication. To provide access for patients, it is recommended PILs are kept in the clinic room or on the ward. Patients should be made aware of their right to see the any relevant PILs, which. In many cases, this is a legal requirement, such as the pharmaceutical industry require patient information leaflets (PILs). We use a range of B3 and B1 perfector sheet fed litho presses with colour management to ensure efficiency and precision. We print on large format sheet sizes of B1 (1020mm x 720mm) and offer various folds and a minimum. Information for patients. Your doctor has referred you for a magnetic resonance imaging scan (MRI). This information leaflet tells you about the scan, how to prepare and what happens during your scan. If you have a specific requirement, need an interpreter, a document in Easy Read, another language, large print


all legal requirements have been met . 1.5.5 Ensure that the patient receives a manufacturer's patient information leaflet with each medicine. 1.5.6 Identify whether patients supplied with a medicine(s) under a PGD are exempt from NHS prescription charges Results. There was no significant difference in STAI or VAS scores for anxiety between the two groups before or after the information leaflets. Significantly more patients who received drug patient information leaflets felt that they had received too much information (0% Group 1 vs 18% Group 2, P=0.003).More than 64% of patients in both groups said that they would not wish to receive detailed. A package insert is a document included in the package of a medication that provides information about that drug and its use. For prescription medications, the insert is technical, providing information for medical professionals about how to prescribe the drug. Package inserts for prescription drugs often include a separate document called a patient package insert with information written in.

Implant Cards and Information Leaflets: Strengthening

  1. The Patient Information Leaflet: The NHS has provided the Patient Information Leaflet to some patients who are being vaccinated. That Patient Information Leaflet does not present the material risks and the material benefits of the vaccination in an adequate way:..read Information on Vaccine Passports: Advertising of the vaccine
  2. Information in Practice pp 263, 264 Leaflets and other information packages (video and audio tapes, computer programs, and websites) have long been seen as integral to educational strategies designed to promote health, persuade people to adopt healthy lifestyles, and increase uptake of screening. They have also been developed to educate patients in self care of such chronic conditions as.
  3. Patient Information Leaflet C T Myelogram Derriford Hospital Derriford Road Plymouth PL6 8DH This is a legal requirement and ensures Legal notice Please remember that this leaflet is intended as general information only. It is not definitive, and the RCR and the BSIR cannot accept an

Lawsuit Over Pharmacy Monograph Patient Information Sheet

Personal information cannot be collected via cookies and other tracking technology, however, if you previously provided personally identifiable information, cookies may be tied to such information. Aggregate cookie and tracking information may be shared with third parties. Cookies are used to collect general online usage by using a cookie file Examples. The following real-life examples have been used in research involving children and young people: Example 1 - OXBAV < 6. Example 2 - OXBAV 6-9. Example 3 - OXBAV 10-15. We'd like to acknowledge Dr Malenka M Bissell, University of Oxford for providing the OXBAV examples. Example 4 - Appendicitis 6-12

Patient information leaflets: informing or frightening? A

  1. Practice Information Leaflet Welcome to Crown Cottage Dental Care We are a friendly, progressive dental practice that offers high quality dental care. We welcome families and patients of all ages and offer a variety of NHS and private dental care. Crown Cottage opened its doors in July 2004. The practice interior is purpose buil
  2. patient information leaflets, he should take every step to eradicate the need for a patient to have to ask a third party to do this. These steps will include: • arranging for audio, large print or Braille versions of the Patient Information Leaflet to be made available to the patient as quickly as possible (e.g. through the X-PIL scheme)
  3. The PGD should also identify any other relevant information or advice to be given to the patient, including providing the statutory manufacturer's Patient Information Leaflet. It should also refer to any other checks that practitioners must carry out to ensure that they and the patient/carer fully understand how to take or use their medicine
  4. leaflets. Ninety-four percent of patients felt the leaflets provided great information or good information to know. Ninety-seven percent felt the information in the leaflets was provided in a way they could understand. Eighty-two percent of patients taking the drug for the first time and 48% of patients who had previously taken the medication.
  5. The provision of good information for patients helps to ensure they understand and fully participate in the decision-making about medicinal gases prescribed or recommended to them by healthcare professionals. The Patient Information Leaflet (PIL) is a legal requirement for pharmaceutical gases and specifically designed to meet this need
  6. It is critical that the contents of the Participant Information Leaflet match the details provided in the Application Form. Do not assume patients will understand words and terms such as 'inclusion', 'exclusion Article 7 GDPR requirements
  7. Title: Patient Information Development and Distribution Policy Version: 3 Issued: 26.11.20 Page 3 of 29 APPENDICIES Appendix 1 Equality Impact Assessment 14 Appendix 2 Environment Impact Assessment 16 Appendix 3 Process Flowchart 17 Appendix 4 Guide to writing patient / public information leaflets 20 Appendix 5 Guidance on leaflet format 2

CFR - Code of Federal Regulations Title 2

There is a legal and ethical duty to obtain informed consent from patients prior to treatment. requirement, but some hospital policies may require this) NHS Blood and Transplant produces a range of patient information leaflets intended to support the consent process. It is important to note that they do not replace the shared decision. The patient leaflet and responses to commonly asked questions for the TPP SystmOne electronic patient record system provides further details as to how your medical information is managed and shared. To access these, 'click' on the links below: TPP SystmOne Frequently Asked Questions. TPP SystmOne Support. Legal Basis for Sharing of Information or interstate requests for information. A patient's HIV information may be made available to clinical staff treating a patient for any condition, where clinically relevant. However, restrictions apply to how HIV information can be used for other purposes. Consent for sharing information Consent for the sharing of information should no To support this, PHE provides all cancer centres with patient information leaflets on cancer registration. These leaflets should be made readily available to patients. If you would like to request copies of the leaflet, please email NDRengagement@phe.gov.uk or you can find more information, and access the leaflet from the National Disease.

Lanes Printers | Pharmaceutical Leaflet Print | Broadstairs

Informed consent requires good communication. Patient information leaflets (PILs) may be helpful, although some PILs are too hard to read for the average patient. We sought to examine the readability of PILs provided for patients prior to endoscopic procedures in 24 gastrointestinal and 16 respiratory departments of 24 Irish public hospitals The hypothesis was that if there was a correlation between the results of these evaluations it would be acceptable to only do expert review for patient information leaflets currently in use. Experts and patients examined patient information leaflets from 30 common medicines, following European Union Directive 92/27 EEC, which outlined the legal. In a clinical study, a multitude of documents are written, recorded, and often translated by the different participants in the process, but from a translation point of view, probably the most important are the Patient Information Leaflet (PIL) and the Informed Consent Form (ICF) - which are basically two documents that always go together and are sometimes combined Since 2010 we have asked for feedback from patients on the clarity and quantity of information we provide in our leaflets. We have had 251 responses: Clarity - On a scale of 1 to 5, where 1 = not clear and 5 = very clear, 90% of responses ticked either 5 (78%) or 4 (12%). Quantity - 79% of responses say the quantity of information given was.

Information to Patients - Legislative approach Public Healt

Information leaflets. If you give the patient an information leaflet to take away, to support and complement your discussions and explanations, make a note about this in the records. Ideally, specify which leaflets or information sheets and which version of them you used discloses and manages a patient's data. It fulfils a legal requirement to protect a patient's privacy. Why do we need one? To ensure compliance with the General Data Protection Regulation (GDPR), WACA must ensure that information is provided to patients about how their personal data is processed in a manner which is PATIENT INFORMATION LEAFLET Bellevue Terrace, Newport, South Wales NP20 2WQ Also at Bettws Health Centre 500 Monnow Way, Bettws, Newport, South Wales NP20 7TD (Currently closed due to Covid-19 restrictions) August 2020 Tel: 01633 256337 Fax: 01633 222856 Website: www.bellevuegp.com Email: Bellevue.Enquiries@wales.nhs.uk Out of Hours Service: 11 1. Put patients' interests first 2. Communicate effectively with patients 3. Obtain valid consent 4. Maintain and protect patients' information 5. Have a clear and effective complaints procedure 6. Work with colleagues in a way that is in patients' best interests 7. Maintain, develop and work within their professional knowledge and skills 8

Supporting Module 1

Part of the patient recruitment process is ensuring that a patient fully understands all aspects of the trial to enable them to comply with the requirements. To support this, they are provided with the Patient Information Leaflet (PIL), however, these documents are lengthy, use technical terms and can be intimidating In the more recently issued guidance (September 2015) it is stated that clinicians, in order to meet the fair processing requirements, should give the patient the FGM leaflet 'More information about FGM' which is available in 11 languages. Further, it is stated that giving the patient this leaflet fully meets the requirement for 'fair.

Biolectra® Magnesium 400 mg ultra Direct | Biolectra

Patient Information Leaflets (PILs) BOC Healthcar

  1. Patient information leaflets/fact sheets are a useful means of providing information on the procedure and the risks, benefits, alternatives and sources of information. All patient information leaflets used must be developed as per the process for writing and producing information for patients
  2. PEG feeding . Making the decision . As a result of many different medical conditions such as stroke, head injury, neurological diseases, or surgery to the head and neck, the muscles involved i
  3. The term 'confidential patient information' is a legal term defined in section 251 (11) of the National Health Service Act 2006. It is information about any patient, alive or dead, that meets the following 3 requirements
  4. 1.1 The Use of Force leaflet is available in hard copy by emailing the Patient Information Centre at pic@cntw.nhs.uk or in digital form via the Trust intranet. It was designed to satisfy the requirements of the Mental Health Units Use of Force Act (Seni's Law) 2018 as detailed in the CNTW Restraint Reduction Policy
  5. leaflets (PLs) for medicines must reflect the results of consultation with target patient groups (user testing) and include within the marketing authorisation, data in module m-1-3-4- of the eCTD, not every leaflet needs be the subject of a separate test. PLs may be able to rely on testing applied to PLs for similar products
  6. The ultimate responsibility for patient care resides with a healthcare professional. This information is intended for the use of patients and caregivers in the United States and Puerto Rico only. Laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country
  7. Objectives The first aim of this study was to quantify the difficulty level of clinical research Patient Information Leaflets/Informed Consent Forms (PILs/ICFs) using validated and widely used readability criteria which provide a broad assessment of written communication. The second aim was to compare these findings with best practice guidelines. Design Retrospective, quantitative analysis of.

Practice leaflet requirements : PSNC Main sit

  1. The respiratory nurse specialists therefore supplemented manufacturer's information with handwritten notes; these were not subject to the quality-control measures applied to trust-approved patient information leaflets (PILs) or the legal obligations demanded by acts of parliament, such as the Equality Act 2010, and DH (2008; 2004) reports
  2. istration. Since January 1, 1999 when European Directive 92/27/EEC 6 came into force, it has been a legal requirement for manufacturers to supply information to patients on the therapeutic indications.
  3. Patients can request services by: [PROVIDER TO PROVIDE CONTACT DETAILS] If you have seen a particular practitioner before you may be able to request to see them again. You qualify for a free NHS funded sight test if you are: • Aged 60 or over • Aged under 16 • Aged 16,17 or 18 in full time education • Diagnosed with diabetes or glaucoma
  4. GP Care produces a wide range of information leaflets and booklets for GPs and Patients. All of the following leaflets are produced free of charge and are available as downloads. NHS Patient Services; Self Funded Services; GP practices can also order batches of pre-printed information leaflets by calling us on 0333 332 2100 or emailing us at.

Presentation: Patient information leaflets - Consumer

How best to use and evaluate Patient Information Leaflets given during a consultation: a systematic review of literature reviews. Source: PubMed (Add filter) Published by Health Expectations : An International Journal Of Public Participation In Health Care And Health Policy, 26 September 2016. review randomized clinical trials (RCT) evaluating. Patient information leaflets and brochures are free of charge. E-mails are free of charge, unless informed otherwise. The charges need to be reviewed regularly to ensure compliance with legislation, and the prices reflect the effort of the fulfilling the job


EU patient information leaflet Focus on Regulatio

Consent model temporary adjustments. Patient consent requirements for electronic Repeat Dispensing (eRD) have been temporarily suspended to encourage wider use of the system during the COVID-19 pandemic. These changes are currently due to remain in place until 31st March 2021, at which point they will be reviewed Patient information leaflet translation. Reliable medication requires reliable translations. For over 25 years, we have been translating patient information leaflets, and we have mastered their unique terminology. Our translations are not only factually accurate, but also easily understood by the patient

Cognisant Researc

does not constitute a legal interpretation of the requirements for patient information leaflets. The CWG recommends that those developing patient information leaflets consult drug regulatory authorities in the countries where they plan to market the product in order to obtain specific requirements on drug labeling and patient information leaflets Patient information leaflet tag sponsored by: Top 25+ Patient information leaflet products on Amazon Template letter yo Doctors Nurses etc about vaccination legal requirements and breache